Ceftobiprole: Farewell or just a delay?

American Journal of Health-System Pharmacy

Volumn 67, Issue 12, 2010, Pages 981-

  Chahine, Elias B ^a  

^a PALM BEACH ATLANTIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CEFTRIAXONE; LINEZOLID; UNCLASSIFIED DRUG; VANCOMYCIN; ZEVTERA;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; COMMUNITY ACQUIRED PNEUMONIA; EDITORIAL; ENTEROCOCCUS FAECALIS; FOOD AND DRUG ADMINISTRATION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 79951720319     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100123     Document Type: Editorial

References (6)

1. Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews. www.idsociety.org/ badbugsnodrugs.html (accessed 2010 Mar 5).
2. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006; 42(suppl 2):S82-9.
3. Dauner DG, Nelson RE, Taketa DC. Ceftobiprole: a novel, broad-spectrum cephalospor in with activity against methicillin-resistant Staphylococcus aureus. Am J Health-Syst Pharm. 2010; 67:983-93.
4. Basilea Pharmaceutica. Press release: Basilea to regain full global right to ceftobiprole. www.basilea.com/chameleon//outbox// f5ff8e93c815aa5768da5f535e421f4c/345229.pdf (accessed 2010 Mar 5).
5. RN Adventures. Replidyne: fare the well faropenem. www.rnaventures. blogspot.com/2008/06/replidyne-fare-wellfaropenem. html (accessed 2010 Mar 25).
6. Pfizer. Press release: Pfizer will withdraw global marketing applications for dalbavancin to conduct a new trial. www.pfizer.be/Media/Press+bulletins/ Research+and+development+and+business+ development/ Withdraw+dalbavancin+market+applications.htm (accessed 2010 Mar 16).